MJH Life Sciences™, owner of The Center for Biosimilars®, has acquired the Pharmacy Benefit Management Institute (PBMI), the nation’s leading provider of research and education that informs, advises, and influences the industry on drug cost management.
MJH Life Sciences™, owner of The Center for Biosimilars®, has announced it has acquired the Pharmacy Benefit Management Institute (PBMI) from Pharmaceutical Strategies Group (PSG). This latest addition to the MJH portfolio broadens its leadership position in managed care at a crucial time for medicine in our country.
“Credible information is critical to healthcare professionals during this global pandemic, and education about how it will impact drug benefit management is vital,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™. “For 25 years, PBMI’s annual meeting has been a driver of change within the marketplace, and as part of our Managed Markets Network, we look forward to growing the conference to make an even bigger impact in the field of managed care.”
As the leading provider of research and education for the pharmacy benefit market, PBMI informs, advises, and influences the industry on drug cost management. PBMI provides a forum for purchasers to exchange ideas and drive marketplace changes that improve pharmacy benefits and control costs. The company offers a wide range of services, including research, continuing education and web resources to help all critical stakeholders work better together to optimize the overall value of drug benefit programs. PBMI is based in Plano, Texas.
“We are appreciative of the many years we have worked in partnership with PBMI,” said Dave Borden, CEO of PSG. “We are proud to have provided a home for PBMI to fulfill its mission to provide quality information and education around best practices and cutting-edge clinical and drug cost management strategies and solutions in community with the industry associates, PBM partners, and PSG friends and colleagues who have supported PBMI conferences and events.
“After careful consideration, we have decided to give PBMI a new home where it can continue its mission and prosper for many years to come,” Borden added. “MJH Life Sciences™ is a global business with significant resources and experience in the area of conference management and education, and we are confident the organization will enable PBMI to further its mission and reach new heights. We look forward to continuing our relationship with PBMI and hope to see our friends, partners, and colleagues at PBMI events for many years to come.”
The sale includes PBMI’s trademarks, conference, website, education and membership assets. All current and future research and analytics projects will continue through PSG under the leadership of Sharon Frazee, Ph.D., MPH, SVP Research & Data Innovation.
About MJH Life Sciences™
MJH Life Sciences™ is the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels, providing health care professionals with the information and resources they need to optimize patient outcomes. MJH combines the reach and influence of its powerful portfolio of digital and print product lines, live events, educational programs and market research with the customization capabilities of a boutique firm. Clients include world-leading pharmaceutical, medical device, diagnostic and biotech companies. For more information, please visit https://www.mjhlifesciences.com/.
The Pharmacy Benefit Management Institute (PBMI) is the nation’s leading provider of research and education that informs, advises and influences the industry on drug cost management. For more information about PBMI visit https://www.pbmi.com/
About The Center for Biosimilars®
The Center for Biosimilars® is a leading website for news and information on developments in the biosimilars industry. With news articles and insightful features on business and clinical developments, conference coverage, expert commentary, and interviews with key opinion leaders, The Center for Biosimilars® keeps readers and viewers around the globe informed and up to date.